News
04-06-2011, 10:23 PM
Circadian Technologies Limited today released data at the American Association for Cancer Research (AACR) annual conference in Orlando, Florida (U.S.A.) demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth and spread in a variety of different mouse models of human cancer.
More... (http://www.news-medical.net/news/20110407/Circadians-VGX-100-neutralises-VEGF-C-and-inhibits-tumour-growth-in-mouse-models-of-human-cancers.aspx)
More... (http://www.news-medical.net/news/20110407/Circadians-VGX-100-neutralises-VEGF-C-and-inhibits-tumour-growth-in-mouse-models-of-human-cancers.aspx)